Trial · NCT02280070
RP II Study of SOX vs mFOLFOX6 in Patients With Resectable Rectal Cancer (KSCC1301).
NCT02280070, Phase 2, Unknown, Clinical Research Support Center Kyush
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. RP II Study of SOX vs mFOLFOX6 in Patients With Resectable Rectal Cancer (KSCC1301). Trials, record NCT02280070. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02280070
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- RP II Study of SOX vs mFOLFOX6 in Patients With Resectable Rectal Cancer (KSCC1301).
- NCT number
- NCT02280070
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 110 participants, estimated
- Lead sponsor
- Clinical Research Support Center Kyush
- Conditions
- Rectal Cancer
- Interventions
Laboratory test, Medical history and physical examination, BW and height, Performance status, Creatinine clearance, Biomarker, Contrasting CT, Adverse event, HBs antigen and HCV antibody, Endoscopy, HBs antibody and HBc antibody, S-1, L-OHP (130mg/m2), L-OHP (85 mg/m2), l-LV, 5-FU
- First posted
- 2014-10-31
- Last updated
- 2014-10-31
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 3-years Disease Free Survival rate | 3 years from the enrollment | The last analysis after the follow-up period is conducted. The disease-free survival ratio that assumed full analysis set (FAS) as a denominator is estimating by Kaplan-Meier method at 3 year, up to 5 years after the last subject enrollment. |
| Secondary | Pathological Effect | After operation, up to 5 years after the last subject enrollment. | The pathological effect of protocol treatment as FAS a denominator is evaluated according to the criteria of Japanese Classification of Colorectal Carcinoma 7th revision |
| Secondary | R0 resection rate | At operation, up to 5 years after the last subject enrollment. | The R0 resection rate is defined as a ratio of case that conducted R0 resection in FAS. |
| Secondary | Completion rate of each modality (neoadjuvant chemotherapy, operation and adjuvant chemotherapy) | After completion of protocol treatment, up to 5 years after the last subject enrollment. | The rate completed 4 courses of neo-adjuvant chemotherapy within protocol treatment is defined as the completion rate of neo-adjuvant therapy in FAS. Among the cases that an resection operation are enforced and that adjuvant chemotherapy is planned after the operation, the rate completed 4 courses of adjuvant chemotherapy within protocol treatment is defined as the completion rate of adjuvant therapy |
| Secondary | Overall survival (OS) | Up to 5 years after the last subject enrollment. | Overall survival is defined as a period from an enrollment date to a death from every cause in FAS. |
| Secondary | Disease Free survival (DFS) | The date of recurrence, occurrence of secondary cancer and death, up to 5 years after the last subject enrollment. | DFS is defined as the period from a registration day to the day of recurrence, the day of diagnosis of secondary cancer and the day of the death of every cause in FAS. |
| Secondary | OS in patients with R0 resection | At the date of death, up to 5 years after the last subject enrollment. | OS in patients with R0 resection is defined as a period from a enrollment day to the date of death from every cause in patients with R0 resection in FAS. |
| Secondary | DFS in patients with R0 resection | The date of recurrence, occurrence of secondary cancer and death, up to 5 years after the last subject enrollment. | DFS in patients with R0 resection is defined as the period from a enrollment day to the day of recurrence, the day of diagnosis of secondary cancer and the day of the death of every cause in patients with R0 resection in FAS. |
| Secondary | Transition rate to Operation | At the operation, up to 5 years after the last subject enrollment. | The transition rate to operation is defined as the rate of case transited to the resection operation in FAS. |
| Secondary | local recurrence rate (per operated population) | After the operation, up to 5 years after the last subject enrollment. | The local recurrence rate is defined as the recurrence rate of operated population. |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02280070
GET https://conductscience.org/api/trials/v1/NCT02280070/registered